drugset / Trial / NCT02053220

Mechanism of Action Trial of ColoAd1

NCT02053220

Phase 1 Completed 17 enrolled Akamis Bio
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.

Timeline

Start
2013-06
Primary completion
2015-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Enadenotucirev Unknown 3e+11 unknown Intravenous
Subject Enadenotucirev Unknown 1e+12 unknown Intravenous